Friday, 16 October 2026European Markets

MOTORK Stock Bullish Momentum With A 17.27% Rise On Monday

Loading stream...

(VIANEWS) - The Market ended the session with MOTORK (MTRK.AS) rising 17.27% to €2.58 on Monday while AEX-Index slid 0.1% to €759.83.

About MOTORK

MotorK plc, together with its subsidiaries, provides software-as-a-service for the automotive retail industry in Europe, the Middle East, and Africa. The company offers a combination of automotive SaaS products and digital solutions to the digital lead generation, management, and nurturing process. It provides technology and software solutions for car manufacturers, dealers, and service centers. The company offers WebSparK, a web platform for traffic acquisition and lead generation performance; LeadSparK, a CRM platform to support the activities of car dealerships and automotive manufacturers; and StockSparK, a stock management platform. It offers dealer websites, as well as CRM and life cycle management, vehicle management, traffic acquisition, and car configurator portal products. The company was incorporated in 2010 and is headquartered in Milan, Italy.

Earnings Per Share

As for profitability, MOTORK has a trailing twelve months EPS of €-0.166.

Volatility

MOTORK's last week, last month's, and last quarter's current intraday variation average was a negative 3.91%, a positive 1.83%, and a positive 3.27%.

MOTORK's highest amplitude of average volatility was 3.91% (last week), 4.71% (last month), and 3.27% (last quarter).

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, MOTORK's stock is considered to be overbought (>=80).

Volume

Today's last reported volume for MOTORK is 25165 which is 20.92% below its average volume of 31826.

More news about MOTORK (MTRK.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com